Levosimendan Kalceks

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer and potassium‑channel opener presented as an intravenous solution for intravenous use. It is indicated for the treatment of acute decompensated heart failure and cardiogenic shock in adult patients. It is used under medical supervision in critical care settings.

GNH USA supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care pharmacies worldwide, ensuring quality and regulatory compliance. The company provides full documentation and support for import and distribution.

Levosimendan is a calcium sensitizer and potassium‑channel opener used in the management of severe heart‑failure syndromes.

- Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. - Cardiogenic shock: stabilizes hemodynamics and supports organ perfusion. - Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility and facilitates weaning from mechanical support.

Levosimendan may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Hypotension: drop in blood pressure, especially after rapid infusion. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal upset. - Dizziness or tachycardia: transient increase in heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Arrhythmias: ventricular tachycardia, atrial fibrillation, or other rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.

Levosimendan requires careful monitoring in several clinical situations.

- Renal impairment: adjust monitoring as drug clearance may be reduced. - Hepatic dysfunction: use with caution due to altered metabolism. - Hypotension: monitor blood pressure closely during and after infusion. - Concurrent vasodilators: risk of additive blood‑pressure lowering effects. - History of arrhythmia: continuous ECG surveillance recommended. - Pregnancy and lactation: safety not established; avoid unless clearly indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilation may cause severe hypotension. - Other calcium sensitizers: combined inotropic effect can lead to excessive cardiac stimulation. - Additional potassium‑channel openers: synergistic vasodilatory response.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired hemodynamic response. - ACE inhibitors or ARBs: can enhance blood‑pressure lowering effect. - Diuretics: may predispose to electrolyte disturbances, especially potassium shifts.